Table 1.
JAK inhibitors currently in use in clinical trials.
| Drug compound | Selectivity | Trial phase | Diseases enrolled |
|---|---|---|---|
| AZD1480 | JAK2 | I/II | PMF, post-PV/ET-MF |
| CEP701 | JAK2 | I/II | PMF, PV, ET, AML |
| CYT387 | JAK1/JAK2 | I/II | PMF, post-PV/ET-MF |
| INCB018424 | JAK1/JAK2 | I/II/III | AML, ALL, MDS, CML, PMF, PV |
| SB1518 | JAK2 | I/II | AML, CML, CMML, MDS, PMF, Lymphoma |
| TG101348 | JAK2 | I/II | PMF |
| LY2784544 | JAK2 | I | PMF, PV, ET |
PMF, primary myelofibrosis; PV, polycythemia vera; ET, essential thrombocytosis; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MF, myelofibrosis.